Literature DB >> 20307189

In vitro cytotoxicity, apoptosis, DNA-binding, and antioxidant activity studies of ruthenium (II) complexes.

Hong-Liang Huang1, Yun-Jun Liu, Cheng-Hui Zeng, Li-Xin He, Fu-Hai Wu.   

Abstract

Two new ligands maip (1) (maip = 2-(3-aminophenyl)imizado[4,5-f][1,10]phenanthroline), paip (2) (paip = 2-(4-aminophenyl)imidazo[4,5-f][1,10]phenanthroline), and their ruthenium (II) complexes [Ru(phen)(2)(maip)](ClO(4))(2) (3) and [Ru(phen)(2)(paip)](ClO(4))(2) (4) (phen = 1,10-phenanthroline) have been synthesized and characterized. The cytotoxicity of these compounds was evaluated by MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] assay. The apoptosis assay was carried out with acridine orange/ethidium bromide staining methods. The DNA-binding behaviors of complexes 3 and 4 were investigated by viscosity measurements, thermal denaturation, photocleavage, and spectroscopic methods. The results show that the two complexes intercalate into the base pairs of DNA. In the presence of a complex, apoptosis of BEL-7402 cells was observed. Experiments show that these compounds exhibit antioxidant activity against hydroxyl radicals.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20307189     DOI: 10.1089/dna.2009.0979

Source DB:  PubMed          Journal:  DNA Cell Biol        ISSN: 1044-5498            Impact factor:   3.311


  2 in total

1.  Molecular aspects on the interaction of isatin-3-isonicotinylhydrazone to deoxyribonucleic acid: model for intercalative drug-DNA binding.

Authors:  Soheila Kashanian; Mohammad Mehdi Khodaei; Parvaneh Pakravan; Hadi Adibi
Journal:  Mol Biol Rep       Date:  2011-07-21       Impact factor: 2.742

2.  Cellular responses of BRCA1-defective and triple-negative breast cancer cells and in vitro BRCA1 interactions induced by metallo-intercalator ruthenium(II) complexes containing chloro-substituted phenylazopyridine.

Authors:  Tidarat Nhukeaw; Pornvichai Temboot; Kanidtha Hansongnern; Adisorn Ratanaphan
Journal:  BMC Cancer       Date:  2014-02-07       Impact factor: 4.430

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.